Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Inhalation (MDI), IV |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.053.579 |
Chemical and physical data | |
Formula | C18H23N5O5 |
Molar mass | 389.412 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Reproterol is a short-acting[1] β2 adrenoreceptor agonist used in the treatment of asthma.[2]
It was patented in 1965 and came into medical use in 1977.[3]
Reproterol contains a stereocenter and is chiral. There are thus two enantiomers, the (R)-form and the (S)-form. The commercial preparations contain the drug as a racemate, an equal mixture of the two enantiomers.[4]
Enantiomers of reproterol | |
---|---|
(R)-Reproterol CAS number: 210710-33-1 |
(S)-Reproterol CAS number: 210710-34-2 |
α1 |
| ||||
---|---|---|---|---|---|
α2 |
| ||||
β |
| ||||